RDX-002 and Triglycerides After Stopping GLP-1 Drugs

TL;DR: This is a small, completed Phase 2 trial (68 adults) testing an investigational drug, RDX-002, against placebo. Results have been posted, but Phase 2 findings are early and preliminary — not proof that the drug works or is safe for wider use.

What the RDX-002 trial set out to test

RDX-002 is an investigational (still-experimental, not yet approved) drug developed by Response Pharmaceuticals. This trial studied whether it can lower triglycerides — a type of fat carried in the blood — specifically the spike that occurs after eating a high-fat meal, known as *postprandial* (after-meal) triglycerides.

The focus was a very specific group: adults who had recently stopped taking a GLP-1 receptor agonist for obesity, such as semaglutide or tirzepatide. These medicines curb appetite and support weight loss, but stopping them can lead to weight regain and shifting metabolic markers. The trial asked whether RDX-002 could help manage blood fats during that transition.

Alongside triglycerides, researchers also tracked body weight and fasting cholesterol as secondary measures.

Who was studied and how

This was a Phase 2, interventional, randomized trial comparing RDX-002 to a placebo (a look-alike pill with no active drug). Key facts to keep in view:

• 68 participants — a small sample
• Adults aged 18 to 65, all sexes
• No healthy volunteers; participants had relevant metabolic concerns
• Participants took RDX-002 or placebo daily for 12 weeks, with clinic checkups every 4 weeks
• The trial ran from September 2024 to May 2025 and is now completed

The primary outcome — the main thing the study was built to measure — was incremental postprandial triglycerides at 12 weeks, meaning the rise in blood triglycerides after a high-fat meal.

What did the posted results report?

The results have been posted, and they compare the investigational drug against placebo across four measures: incremental postprandial triglycerides, total postprandial triglycerides, body weight, and the proportion of participants with a 5% increase in body weight.

The registry lists these as the reported outcome measures. It does not, in the facts provided here, give specific effect sizes or a clear-cut verdict. So the honest summary is: the trial measured whether RDX-002 changed after-meal triglyceride levels (and weight-related markers) compared to placebo, and those results are now on record — but the numbers and interpretation should be read directly from the full posted data and any peer-reviewed publication that follows.

If you track your own metabolic health, advanced blood biomarkers and body composition analysis are the kinds of tests that capture the triglyceride and weight measures this trial examined.

Frequently asked questions